Deal Watch: Henlius Licenses Rituximab and Trastuzumab Products to Abbott in Brazil
Purple Book Updates
Health Canada Approves Celltrion’s Adalimumab Biosimilar, YUFLYMA
Year in Review: Top Legal Developments of 2021 Impacting Biosimilars
Tanvex and Biocad announce Phase III results at ESMO Congress
Tanvex and Biocad announce Phase III results at ESMO Congress
Subscribe: Subscribe via RSS
Blogs
Firm/Org